MRS2500 (2 mg/kg; i.v.) decreases acute systemic thromboembolism through selective inhibition of the P2Y1 receptor[3].
?
MRS2500 exhibited strong antithrombotic efficacy in the prevention of arterial thrombosis in the monkey ECAT model[4]..
| Animal Model: | 20-25 g WT Male mice (acute vascular occlusion model)[3] |
| Dosage: | 2 mg/kg |
| Administration: | Intravenous |
| Result: | Reduced platelet consumption.
|